Eli Lilly And Co (LLY) Short Interest Update

Eli Lilly And Co (NYSE:LLY) was the target of a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 103,663,031 shares, an increase of 193.9% from the February 15th total of 35,274,912 shares. Based on an average daily trading volume, of 22,593,431 shares, the short-interest ratio is presently 4.6 days. Approximately 11.3% of the shares of the company are sold short.

Several research firms have recently commented on LLY. Citigroup set a $124.00 price objective on Eli Lilly And Co and gave the stock a “hold” rating in a research note on Tuesday, February 26th. JPMorgan Chase & Co. began coverage on Eli Lilly And Co in a research note on Tuesday. They issued an “overweight” rating and a $140.00 price objective for the company. Cantor Fitzgerald restated a “buy” rating on shares of Eli Lilly And Co in a research note on Monday, February 4th. Zacks Investment Research lowered Eli Lilly And Co from a “buy” rating to a “hold” rating in a research note on Tuesday, December 4th. Finally, UBS Group reduced their price objective on Eli Lilly And Co from $107.53 to $100.00 and set an “average” rating for the company in a research note on Friday, February 8th. Eleven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Eli Lilly And Co currently has a consensus rating of “Buy” and an average target price of $113.06.

In other news, SVP Enrique A. Conterno sold 25,000 shares of the company’s stock in a transaction on Friday, February 15th. The stock was sold at an average price of $121.00, for a total value of $3,025,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 51,766 shares of the company’s stock in a transaction on Tuesday, January 15th. The stock was sold at an average price of $117.74, for a total value of $6,094,928.84. Following the completion of the sale, the insider now owns 117,963,538 shares of the company’s stock, valued at $13,889,026,964.12. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 833,190 shares of company stock valued at $102,388,102. Company insiders own 0.11% of the company’s stock.

Institutional investors have recently modified their holdings of the stock. Systematic Financial Management LP bought a new position in shares of Eli Lilly And Co during the 3rd quarter valued at about $2,123,000. MML Investors Services LLC boosted its holdings in shares of Eli Lilly And Co by 42.1% during the 3rd quarter. MML Investors Services LLC now owns 25,988 shares of the company’s stock valued at $2,789,000 after purchasing an additional 7,698 shares during the last quarter. Commonwealth Bank of Australia boosted its holdings in shares of Eli Lilly And Co by 6.3% during the 3rd quarter. Commonwealth Bank of Australia now owns 72,261 shares of the company’s stock valued at $7,749,000 after purchasing an additional 4,300 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. boosted its holdings in shares of Eli Lilly And Co by 145.0% during the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 6,818 shares of the company’s stock valued at $732,000 after purchasing an additional 4,035 shares during the last quarter. Finally, DE Burlo Group Inc. bought a new position in shares of Eli Lilly And Co during the 3rd quarter valued at about $8,361,000. 77.00% of the stock is owned by institutional investors.

Shares of Eli Lilly And Co stock opened at $123.94 on Friday. The firm has a market capitalization of $127.87 billion, a P/E ratio of 22.33, a PEG ratio of 2.49 and a beta of 0.33. The company has a quick ratio of 1.38, a current ratio of 1.73 and a debt-to-equity ratio of 1.07. Eli Lilly And Co has a fifty-two week low of $74.51 and a fifty-two week high of $130.75.

Eli Lilly And Co (NYSE:LLY) last issued its earnings results on Wednesday, February 6th. The company reported $1.33 earnings per share for the quarter, missing the consensus estimate of $1.36 by ($0.03). The firm had revenue of $6.44 billion during the quarter, compared to the consensus estimate of $6.28 billion. Eli Lilly And Co had a return on equity of 44.66% and a net margin of 13.16%. The company’s quarterly revenue was up 4.5% on a year-over-year basis. During the same period in the prior year, the company posted $1.14 EPS. On average, sell-side analysts forecast that Eli Lilly And Co will post 5.62 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Friday, March 8th. Investors of record on Friday, February 15th were issued a $0.645 dividend. The ex-dividend date of this dividend was Thursday, February 14th. This represents a $2.58 annualized dividend and a yield of 2.08%. This is an increase from Eli Lilly And Co’s previous quarterly dividend of $0.56. Eli Lilly And Co’s dividend payout ratio is currently 46.49%.

ILLEGAL ACTIVITY WARNING: This report was published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://sportsperspectives.com/2019/03/16/eli-lilly-and-co-lly-short-interest-update.html.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: What are defining characteristics of a correction?

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.